AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|AAPL339.84-3.11 (-0.91%) ▼|ABBV290.72+8.04 (+2.85%) ▲|ABT102.61-1.46 (-1.40%) ▼|ACN238.96+2.03 (+0.86%) ▲|ADBE255.26+8.17 (+3.30%) ▲|AMAT406.46-6.65 (-1.61%) ▼|AMD542.18+4.13 (+0.77%) ▲|AMGN434.83+9.89 (+2.33%) ▲|AMT184.65+1.62 (+0.88%) ▲|AMZN263.10+0.65 (+0.25%) ▲|AVGO335.28+0.69 (+0.21%) ▲|AXP319.86+3.45 (+1.09%) ▲|BA191.31-0.12 (-0.06%) ▼|BAC50.80+0.41 (+0.81%) ▲|BKNG164.47+1.87 (+1.15%) ▲|BLK1,129.24+4.64 (+0.41%) ▲|BMY61.60+2.77 (+4.71%) ▲|BNY144.36+1.92 (+1.35%) ▲|BRK-B537.93+5.70 (+1.07%) ▲|C122.39+0.70 (+0.58%) ▲|CAT726.45+0.66 (+0.09%) ▲|CL94.02+1.16 (+1.24%) ▲|CMCSA22.21+0.31 (+1.39%) ▲|COF201.93+2.10 (+1.05%) ▲|COP145.84+0.60 (+0.41%) ▲|COST995.38-0.15 (-0.02%) ▼|CRM242.07-0.39 (-0.16%) ▼|CSCO106.63+0.13 (+0.12%) ▲|CVS94.11+1.43 (+1.54%) ▲|CVX224.76+0.39 (+0.17%) ▲|DE636.27+9.27 (+1.48%) ▲|DHR225.45+1.02 (+0.45%) ▲|DIS111.60+2.01 (+1.83%) ▲|DUK121.25+1.98 (+1.66%) ▲|EMR159.79-0.76 (-0.47%) ▼|FDX300.57+6.79 (+2.31%) ▲|GD344.41+2.98 (+0.87%) ▲|GE299.48-11.80 (-3.79%) ▼|GEV896.82-11.62 (-1.28%) ▼|GILD156.32+3.25 (+2.12%) ▲|GM75.90-6.86 (-8.28%) ▼|GOOG336.78-3.38 (-0.99%) ▼|GOOGL340.69-3.49 (-1.01%) ▼|GS885.74+9.96 (+1.14%) ▲|HD315.78+5.90 (+1.90%) ▲|HON212.18+2.20 (+1.05%) ▲|IBM240.33+3.94 (+1.67%) ▲|INTC92.54+0.51 (+0.55%) ▲|INTU336.52+10.90 (+3.35%) ▲|ISRG438.78+5.60 (+1.29%) ▲|JNJ259.72+5.93 (+2.34%) ▲|JPM335.76+2.23 (+0.67%) ▲|KO92.75-0.68 (-0.72%) ▼|LIN499.70-3.75 (-0.74%) ▼|LLY1,292.02+51.68 (+4.17%) ▲|LMT549.29+1.06 (+0.19%) ▲|LOW199.33+3.41 (+1.74%) ▲|LRCX265.14-7.06 (-2.59%) ▼|MA622.00+5.60 (+0.91%) ▲|MCD245.62+2.95 (+1.21%) ▲|MDLZ63.87+0.53 (+0.83%) ▲|MDT94.57+1.80 (+1.94%) ▲|META690.14-15.30 (-2.17%) ▼|MMM171.17+9.16 (+5.65%) ▲|MO74.43+0.34 (+0.46%) ▲|MRK148.25+4.62 (+3.22%) ▲|MS180.42+1.95 (+1.09%) ▲|MSFT532.48-1.04 (-0.19%) ▼|MU909.62+4.72 (+0.52%) ▲|NEE78.83+0.66 (+0.84%) ▲|NFLX69.29-0.56 (-0.80%) ▼|NKE37.95+0.74 (+1.98%) ▲|NOW149.61+4.25 (+2.92%) ▲|NVDA217.09+0.00 (+0.00%) ▲|ORCL131.78+2.19 (+1.69%) ▲|PEP134.26+0.69 (+0.52%) ▲|PFE30.24+0.80 (+2.70%) ▲|PG158.22+0.53 (+0.33%) ▲|PLTR195.76+1.61 (+0.83%) ▲|PM200.05-1.00 (-0.50%) ▼|QCOM176.25+2.72 (+1.57%) ▲|RTX191.57-0.55 (-0.28%) ▼|SBUX99.44+1.57 (+1.60%) ▲|SCHW90.69+1.11 (+1.24%) ▲|SO90.80+1.53 (+1.71%) ▲|SPG205.95+3.46 (+1.71%) ▲|T23.55+0.35 (+1.49%) ▲|TMO690.26+10.88 (+1.60%) ▲|TMUS157.96+1.87 (+1.20%) ▲|TSLA374.66+6.60 (+1.79%) ▲|TXN279.33+3.18 (+1.15%) ▲|UBER69.00-0.96 (-1.37%) ▼|UNH420.66+13.78 (+3.39%) ▲|UNP288.10+1.09 (+0.38%) ▲|UPS99.00+1.54 (+1.58%) ▲|USB58.91+1.06 (+1.83%) ▲|V407.29+4.37 (+1.08%) ▲|VZ44.56+0.41 (+0.92%) ▲|WFC81.64-0.17 (-0.20%) ▼|WMT118.35-0.35 (-0.29%) ▼|XOM177.16-1.12 (-0.63%) ▼|
20.2 C
New York
Tuesday, October 20, 2026

Tag: clinical trial

newsFORsourcecompanycontentinformation1releasesmarket

Constantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease Therapies

WATERTOWN, Mass. and CINCINNATI, June 18, 2026 (GLOBE NEWSWIRE) -- Constantiam Biosciences and Cincinnati Children's today announced a strategic collaboration through an exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3).

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development 
Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Reported positive clinical proof-of-concept data for OD-001 in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis.

ARMR Sciences Achieves Major Milestone Toward Overdose Protection, Produces First-Ever Anti-Fentanyl Immune Response in Humans

Interim phase 1/2 data confirm significant anti-fentanyl antibody production at the lowest dose, with a well-tolerated safety profile across all patients dosed. NEW YORK,...

Matricelf Advances Toward First in Human Trial Following Successful GLP Safety Study Completion

TEL AVIV, Israel, June 17, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury,...

Steer Health Wins 2026 Hearst Health Prize

$125,000 in Hearst Health Prize awards recognize Steer Health and finalist Dana-Farber Cancer Institute for innovative uses of data science to improve health outcomesLOS...

Azitra, Inc. to Present at 2026 BIO International Convention

BRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...

Silexion Therapeutics to Attend BIO International Convention 2026

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company’s Chief Executive Officer, Ilan Hadar, and the Company’s Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.  

Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.

Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED

– ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect –

Stem Cell Therapy Market worth $3.65 billion by 2035 | MarketsandMarkets™

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Stem Cell Therapy Market is projected to grow from about USD 0.48 billion...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers